Experimental: ALZ-801

Phase 3Small molecule

Experimental: ALZ-801 is one of 2 small molecule programs targeting Early Alzheimer's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Early Alzheimer's DiseaseTerminated

Early Alzheimer's DiseasePhase 3

Terminated

Competition

Competitive Landscape

3 competitors in Early Alzheimer's Disease

#DrugCompanyPhaseTrials

Experimental: ALZ-801

AAlzheon Inc.

Phase 3

1 2

MK-2214

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Completed·AAlzheon Inc.·Phase 3·NCT04770220·325 enrolled

Early Alzheimer's Disease1 trial

Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

Terminated·AAlzheon Inc.·Phase 3·NCT06304883·163 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Experimental: ALZ-801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Experimental: ALZ-801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Experimental: ALZ-801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alzheon Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlzheon Inc.

Experimental: ALZ-801

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

Early Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News